Forma Therapeutics Appoints Two New Vice Presidents to Lead Key Organizational Functions

Kymera Therapeutics Appoints Biopharma Veterans Pamela Esposito and Jeff Albers to its Board of Directors

Forma Therapeutics Appoints Biopharma Veteran Thomas G. Wiggans To Board Of Directors

Nimbus Therapeutics Appoints Veteran Pharmaceutical Chemist Scott Edmondson, Ph.D., as Senior Vice President, Head of Chemistry

Kymera Therapeutics Appoints Dr. Richard Chesworth as Chief Scientific Officer

Kymera Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement

Protagonist Appoints Sarah O’Dowd to Board of Directors

Forma Therapeutics Elects Distinguished Researcher And Physician Wayne A.I. Frederick, M.D., To Board Of Directors

Kymera Therapeutics and Sanofi Enter into Strategic Partnership to Advance Novel Protein Degrader Therapies to Patients

Forma Therapeutics Announces Closing Of Initial Public Offering And Exercise In Full Of The Underwriters’ Option To Purchase Additional Shares

Nimbus Therapeutics Presents Data on Novel HPK1 Inhibitor, Demonstrating Robust Inhibition of Tumor Growth In Vivo

Hepcidin Mimetic PTG-300 Receives U.S. FDA Orphan Drug Designation for the Treatment of Polycythemia Vera

Forma Therapeutics Presents Safety, Pharmacokinetic And Pharmacodynamic Data From Phase 1 Clinical Trial For Investigational Agent FT-4202 In Patients With Sickle Cell Disease

Nimbus Therapeutics Announces Expansion of its Drug Discovery Pipeline Across Oncology, Immunology and Metabolism

Kymera Therapeutics Initiates Enrollment in Non-Interventional Trial Evaluating IRAK4 Role in Patients with Hidradenitis Suppurativa and Atopic Dermatitis

Aeglea BioTherapeutics Announces 1-Year Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 6th Congress of the European Academy of Neurology

Surface Oncology and Merck to Collaborate on Immuno-Oncology Study Evaluating SRF617, Targeting CD39 in Combination with KEYTRUDA® (pembrolizumab) in Solid Tumor Patients

Surface Oncology to Present Preclinical Data for Multiple Product Programs at the American Association for Cancer Research Annual Meeting

Nimbus Therapeutics Announces Identification of a Potent, Selective HPK1 Inhibitor with Robust In Vivo Activity

Protagonist Therapeutics Announces Initial Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera

Forma Therapeutics Appoints David N. Cook, Ph.D., To Chief Scientific Officer

Surface Oncology Announces First Patient Dosed in Clinical Trial of Immuno-Oncology Antibody SRF388

Forma Therapeutics Announces Preclinical Data Demonstrating Antitumor Activity Of A Potent And Selective Inhibitor Of CBP/P300 For Androgen Receptor Positive Cancers To Be Presented At The American Association For Cancer Research

FORMA Therapeutics Receives FDA Orphan Drug Designation For FT-4202 For The Treatment Of Sickle Cell Disease

Aeglea BioTherapeutics Announces Approval of Clinical Trial Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)

Surface Oncology Announces First Patient Dosed in Clinical Trial of Immuno-Oncology Candidate SRF617

Sutro Biopharma Announces Extension of First Cytokine Derivative Research Program Under Collaboration with Merck

Kymera Therapeutics Announces $102 Million Series C Financing to Advance its Protein Degrader Pipeline and Platform

FORMA Therapeutics Announces FT-4202 Granted Fast Track Designation And Rare Pediatric Disease Designation For Treatment Of Sickle Cell Disease

Mycovia Pharmaceuticals Initiates Extension Clinical Studies to Further Evaluate Long-Term Efficacy of Oteseconazole (VT-1161) in Patients with Recurrent Vulvovaginal Candidiasis

FORMA Reports Achievement Of Early-Stage Clinical Development Milestones For Assets Licensed Exclusively To Boehringer Ingelheim And Bristol-Myers Squibb

Aeglea BioTherapeutics Submits CTA Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)

Protagonist Therapeutics Achieves Milestone in Janssen Biotech, Inc., Collaboration

Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Hereditary Hemochromatosis